Abstract
Aim:
To characterize pharmacokinetic-pharmacodynamic modeling of diclofenac in Freund's complete adjuvant (FCA)-induced arthritic rats using prostaglandin E2 (PGE2) as a biomarker.
Methods:
The pharmacokinetics of diclofenac was investigated using 20-day-old arthritic rats. PGE2 level in the rats was measured using an enzyme immunoassay. A pharmacokinetic-pharmacodynamic (PK-PD) model was developed to illustrate the relationship between the plasma concentration of diclofenac and the inhibition of PGE2 production. The inhibition of diclofenac on lipopolysaccharide (LPS)-induced PGE2 production in blood cells was investigated in vitro.
Results:
Similar pharmacokinetic behavior of diclofenac was found both in normal and FCA-induced arthritic rats. Diclofenac significantly decreased the plasma levels of PGE2 in both normal and arthritic rats. The inhibitory effect on PGE2 levels in the plasma was in proportion to the plasma concentration of diclofenac. No delay in the onset of inhibition was observed, suggesting that the effect compartment was located in the central compartment. An inhibitory effect sigmoid Imax model was selected to characterize the relationship between the plasma concentration of diclofenac and the inhibition of PGE2 production in vivo. The Imax model was also used to illustrate the inhibition of diclofenac on LPS-induced PGE2 production in blood cells in vitro.
Conclusion:
Arthritis induced by FCA does not alter the pharmacokinetic behaviors of diclofenac in rats, but the pharmacodynamics of diclofenac is slightly affected. A PK-PD model characterizing an inhibitory effect sigmoid Imax can be used to fit the relationship between the plasma PGE2 and diclofenac levels in both normal rats and FCA-induced arthritic rats.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Burian M, Geisslinger G . COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005; 107: 139–54.
Vásquez-Bahena DA, Salazar-Morales UE, Ortiz MI, Castañeda-Hernández G, Trocóniz IF . Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. Br J Pharmacol 2010; 159: 176–87.
Menasse R, Hedwell P, Kraetz J, Pericin C, Riesterer L, Sallman A, et al. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 1978; 22: 5–16.
Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232–5.
Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL . Pharmacokinetic pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 2005; 146: 642–53.
Torres-Lopez JE, Lopez-Munoz FJ, Castaneda-Hernandez G, Flores-Murrieta FJ, Granados-Soto V . Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effect of diclofenac in the rat. J Pharmacol Exp Ther 1997; 282: 685–90.
Granados-Soto V, Lopez-Munoz FJ, Hong E, Flores-Murrieta FJ . Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. J Pharmacol Exp Ther 1995; 272: 352–6.
Josa M, Urizar JP, Rapado J, Dios-Vieitez C, Castaneda-Hernandez G, Flores-Murrieta F, et al. Pharmacokinetic pharmacodynamic modelling of antipyretic and anti-inflammatory effects of naproxen in the rat. J Pharmacol Exp Ther 2001; 297: 198–205.
Jeunesse EC, Bargues IA, Toutain CE, Lacroix MZ, Letellier IM, Giraudel JM, et al. Paw inflammation model in dogs for preclinical pharmacokinetic pharmacodynamic investigations of nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 2011; 338: 548–58.
Toutain PL, Cester CC, Haak T, Laroute V . A pharmacokinetic- pharmacodynamic approach vs a dose titration for the determination of a dosage regimen: the case of nimesulide, a COX-2 selective nonsteroidal anti-inflammatory drug in the dog. J Vet Pharmacol Ther 2001; 24: 43–55.
Flores-Murrieta FJ, Ko HC, Flores-Acevedo DM, López-Muñoz FJ, Jusko WJ, Sale ME, et al. Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. J Pharmacokinet Biopharm 1998; 26: 547–57.
Huntjens DR, Danhof M, Della Pasqua OE . Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 2005; 44: 846–59.
Lepist EI, Jusko WJ . Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther 2004; 27: 211–8.
Huntjens DR, Spalding DJ, Danhof M, Della Pasqua OE . Correlation between in vitro and in vivo concentration effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol 2006; 148: 396–404.
Huntjens DR, Strougo A, Chain A, Metcalf A, Summerfield S, Spalding DJ, et al. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol 2008; 153: 1072–84.
Huntjens DR, Spalding DJ, Danhof M, Della Pasqua OE . Impact of chronic inflammation on the pharmacokinetic pharmacodynamic relationship of naproxen. Eur J Pain 2010; 14: 227.e1–10.
Wei W, Chen MZ, Xu SY . Pharmacological effects of isoxicam. Chin Pharmacol Bull 1986; 2: 29–34.
Fletcher DS, Widmer WR, Luell S, Christen A, Orevillo C, Shah S, et al. Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J Pharmacol Exp Ther 1998; 284: 714–21.
Gu WZ, Brandwein SR . Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol 1998; 20: 389–400.
Blain H, Boileau C, Lapicque F, Nédélec E, Loeuille D, Guillaume C, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 2002; 53: 255–65.
Wang DL, Liu L, Deng YX, Liu HY, Xie L, Liu XD, et al. Effects of ginkgolide B on the pharmacokinetics and pharmacodynamics of diclofenac, a substrate of cytochrome P450 2C9, in rats. Chin New Drug J 2008; 17: 919–26.
Banik RK, Kasai M, Mizumura K . Reexamination of the difference in susceptibility to adjuvant-induced arthritis among LEW/Crj, Slc/Wistar/ST and Slc/SD rats. Exp Anim 2002; 51: 197–201.
Krekels EH, Angesjö M, Sjögren I, Möller KA, Berge OG, Visser SA . Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. Pharm Res 2011; 28: 1561–76.
Projean D, Dautrey S, Vu HK, Groblewski T, Brazier JL, Ducharme J . Selective downregulation of hepatic cytochrome P450 expression and activity in a rat model of inflammatory pain. Pharm Res 2005; 22: 62–70.
Uno S, Fujii A, Komura H, Kawase A, Iwaki M . Prediction of metabolic clearance of diclofenac in adjuvant-induced arthritis rats using a substrate depletion assay. Xenobiotica 2008; 38: 482–95.
Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C . Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997; 48: 623–31.
Gozzi P, Påhlman, I, Palmér, L, Grönberg A, Persson S . Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-α levels in the mouse. J Pharmacol Exp Ther 1999; 291: 199–203.
Geldof M, Freijer JI, Peletier LA, van Beijsterveldt L, Danhof M . Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. Eur J Pharm Sci 2008; 33: 217–29.
Giuliano F, Warner TD . Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther 2002; 303: 1001–6.
Acknowledgements
This work was supported by funds from the Graduate Student Research and Innovation Program of Jiangsu Province (Grants No CX10B-383Z, 2010) and by funding for innovative research team in institution of Jiangsu higher education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, J., Li, P., Guo, Hf. et al. Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund's complete adjuvant-induced arthritic rats. Acta Pharmacol Sin 33, 1372–1378 (2012). https://doi.org/10.1038/aps.2012.67
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2012.67
Keywords
This article is cited by
-
Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity
Acta Pharmacologica Sinica (2016)
-
Pharmacometrics: a quantitative tool of pharmacological research
Acta Pharmacologica Sinica (2012)
